Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Thoughts on pan can deal

<< Previous

Bullboard Posts

Next >>

Comment by Azzak34on Jun 24, 2023 10:12am

203 Views

Post# 35512728

RE:RE:RE:RE:RE:RE:Thoughts on pan can deal

Pela could be a few years away from hitting the market, unless we get accelerated approval which looks more and more likely. The premium that goes with great phase 3 results is the risk for big pharma right now. If they wait and we get more confirmation of Pelas ability the price goes up exponentially and the bidding war will push that even higher. The argument is how quickly do they acquire to save themselves some money amd beat the competition to Pela, that's all that matters now.

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December